CompletedNCT01457339

SPD489 or Placebo: Safety and Drug Levels in Schizophrenia

About this title

This study evaluated the safety of SPD489 (Lisdexamfetamine dimesylate) for people with schizophrenia.

Medication studyAges 18–65United States

The study in practice

Understand this study

This study evaluated the safety of SPD489 (Lisdexamfetamine dimesylate) for people with schizophrenia.

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations: Glendale and 1 more locationSee all locations and recruitment
Study phase: Phase 1

Study clarity

Study start dateStarted: October 21, 2011

Recruitment status: Completed
Enrollment listed in the registry: 31
Sponsor: Shire
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: United States
Age range: From 18 Years to 65 Years
Official registry ID: NCT01457339
Official title: Show the full official title
A Phase 1, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending, Multiple Oral Doses of SPD489 (Lisdexamfetamine Dimesylate) in Clinically Stable Adults With Schizophrenia

Completed

Glendale · Long Beach

FAQ

What did researchers investigate?

This study evaluated the safety of SPD489 (Lisdexamfetamine dimesylate) for people with schizophrenia.

Who is behind this study?

The study sponsor is Shire.

Did this study involve medication?

Yes. The study involved medication, including SPD489 (Lisdexamfetamine dimesylate) and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.